Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters

Database
Language
Publication year range
1.
Bioorg Med Chem Lett ; 27(18): 4383-4388, 2017 09 15.
Article in English | MEDLINE | ID: mdl-28838698

ABSTRACT

A series of 1-substituted 3-(t-butyl/trifluoromethyl)pyrazole C-region analogues of 2-(3-fluoro-4-methylsulfonamidophenyl)propanamides were investigated for hTRPV1 antagonism. The structure activity relationship indicated that the 3-chlorophenyl group at the 1-position of pyrazole was the optimized hydrophobic group for antagonistic potency and the activity was stereospecific to the S-configuration, providing exceptionally potent antagonists 13S and 16S with Ki(CAP)=0.1nM. Particularly significant, 13S exhibited antagonism selective for capsaicin and NADA and not for low pH or elevated temperature. Both compounds also proved to be very potent antagonists for rTRPV1, blocking in vivo the hypothermic action of capsaicin, consistent with their in vitro mechanism. The docking study of compounds 13S and 16S in our hTRPV1 homology model indicated that the binding modes differed somewhat, with that of 13S more closely resembling that of GRT12360.


Subject(s)
Mesylates/pharmacology , Phenylpropionates/pharmacology , Pyrazoles/pharmacology , TRPV Cation Channels/antagonists & inhibitors , Dose-Response Relationship, Drug , Humans , Mesylates/chemical synthesis , Mesylates/chemistry , Models, Molecular , Molecular Structure , Phenylpropionates/chemical synthesis , Phenylpropionates/chemistry , Pyrazoles/chemistry , Structure-Activity Relationship
2.
Bioorg Med Chem ; 21(13): 3821-30, 2013 Jul 01.
Article in English | MEDLINE | ID: mdl-23643900

ABSTRACT

In an effort to design inhibitors of human glutaminyl cyclase (QC), we have synthesized a library of N-aryl N-(5-methyl-1H-imidazol-1-yl)propyl thioureas and investigated the contribution of the aryl region of these compounds to their structure-activity relationships as cyclase inhibitors. Our design was guided by the proposed binding mode of the preferred substrate for the cyclase. In this series, compound 52 was identified as the most potent QC inhibitor with an IC50 value of 58 nM, which was two-fold more potent than the previously reported lead 2. Compound 52 is a most promising candidate for future evaluation to monitor its ability to reduce the formation of pGlu-Aß and Aß plaques in cells and transgenic animals.


Subject(s)
Aminoacyltransferases/antagonists & inhibitors , Enzyme Inhibitors/chemistry , Enzyme Inhibitors/pharmacology , Thiourea/analogs & derivatives , Thiourea/pharmacology , Alzheimer Disease/drug therapy , Aminoacyltransferases/metabolism , Drug Design , HEK293 Cells , Humans , Inhibitory Concentration 50
3.
Bioorg Med Chem ; 20(1): 215-24, 2012 Jan 01.
Article in English | MEDLINE | ID: mdl-22169633

ABSTRACT

Structure-activity relationships for the A-region in a series of N-4-t-butylbenzyl 2-(4-methylsulfonylaminophenyl) propanamides as TRPV1 antagonists have been investigated. Among them, the 3-fluoro analogue 54 showed high binding affinity and potent antagonism for both rTRPV1 and hTRPV1 in CHO cells. Its stereospecific activity was demonstrated with marked selectivity for the (S)-configuration (54S versus 54R). A docking study of 54S with our hTRPV1 homology model highlighted crucial hydrogen bonds between the ligand and the receptor contributing to its potency.


Subject(s)
Amides/chemistry , Amides/pharmacology , TRPV Cation Channels/antagonists & inhibitors , Amides/chemical synthesis , Animals , Binding Sites , CHO Cells , Computer Simulation , Cricetinae , Cricetulus , Humans , Hydrogen Bonding , Protein Binding/drug effects , Protein Structure, Tertiary , Rats , Stereoisomerism , Structure-Activity Relationship , TRPV Cation Channels/metabolism
4.
Bioorg Med Chem ; 20(3): 1310-8, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22227463

ABSTRACT

On the basis of the previous lead N-4-t-butylbenzyl 2-(3-fluoro-4-methylsulfonylaminophenyl) propanamide (3) as a potent TRPV1 antagonist, structure-activity relationships for the B (propanamide part) and C-region (4-t-butylbenzyl part) have been investigated for rTRPV1 in CHO cells. The B-region was modified with dimethyl, cyclopropyl and reverse amides and then the C-region was replaced with 4-substituted phenyl, aryl alkyl and diaryl alkyl derivatives. Among them, compound 50 showed high binding affinity with K(i)=21.5nM, which was twofold more potent than 3 and compound 54 exhibited potent antagonism with K(i(ant))=8.0nM comparable to 3.


Subject(s)
Analgesics/chemistry , Analgesics/pharmacology , Mesylates/chemistry , Mesylates/pharmacology , Phenylpropionates/chemistry , Phenylpropionates/pharmacology , TRPV Cation Channels/antagonists & inhibitors , Animals , CHO Cells , Cricetinae , Humans , Rats , Structure-Activity Relationship , TRPV Cation Channels/metabolism
5.
J Med Chem ; 64(1): 370-384, 2021 01 14.
Article in English | MEDLINE | ID: mdl-33385210

ABSTRACT

Among a series of benzopyridone-based scaffolds investigated as human transient receptor potential vanilloid 1 (TRPV1) ligands, two isomeric benzopyridone scaffolds demonstrated a consistent and distinctive functional profile in which 2-oxo-1,2-dihydroquinolin-5-yl analogues (e.g., 2) displayed high affinity and potent antagonism, whereas 1-oxo-1,2-dihydroisoquinolin-5-yl analogues (e.g., 3) showed full agonism with high potency. Our computational models provide insight into the agonist-antagonist boundary of the analogues suggesting that the Arg557 residue in the S4-S5 linker might be important for sensing the agonist binding and transmitting signals. These results provide structural insights into the TRPV1 and the protein-ligand interactions at a molecular level.


Subject(s)
Drug Discovery , Pyridones/chemistry , TRPV Cation Channels/agonists , TRPV Cation Channels/antagonists & inhibitors , Animals , Humans , Molecular Structure , Structure-Activity Relationship , Urea/chemistry
6.
J Med Chem ; 63(1): 418-424, 2020 01 09.
Article in English | MEDLINE | ID: mdl-31702924

ABSTRACT

Paradoxically, some TRPV1 agonists are, at the organismal level, both nonpungent and clinically useful as topical analgesics. Here, we describe the scaled-up synthesis and characterization in mouse models of a novel, nonpungent vanilloid. Potent analgesic activity was observed in models of neuropathic pain, and the compound blocked capsaicin induced allodynia, showing dermal accumulation with little transdermal absorption. Finally, it displayed much weaker systemic toxicity compared to capsaicin and was negative in assays of genotoxicity.


Subject(s)
Analgesics/therapeutic use , Phenylurea Compounds/therapeutic use , TRPV Cation Channels/agonists , Thiazoles/therapeutic use , Analgesics/chemical synthesis , Analgesics/pharmacokinetics , Analgesics/toxicity , Animals , CHO Cells , Capsaicin , Cricetulus , Drug Discovery , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Mice, Inbred ICR , Neuralgia/drug therapy , Phenylurea Compounds/chemical synthesis , Phenylurea Compounds/pharmacokinetics , Phenylurea Compounds/toxicity , Swine , Thiazoles/chemical synthesis , Thiazoles/pharmacokinetics , Thiazoles/toxicity
7.
J Med Chem ; 60(19): 8246-8252, 2017 10 12.
Article in English | MEDLINE | ID: mdl-28892388

ABSTRACT

Transient receptor potential vanilloid 1 (TRPV1) has emerged as a promising therapeutic target. While radiolabeled resiniferatoxin (RTX) has provided a powerful tool for characterization of vanilloid binding to TRPV1, TRPV1 shows 20-fold weaker binding to the human TRPV1 than to the rodent TRPV1. We now describe a tritium radiolabeled synthetic vanilloid antagonist, 1-((2-(4-(methyl-[3H])piperidin-1-yl-4-[3H])-6-(trifluoromethyl)pyridin-3-yl)methyl)-3-(3-oxo-3,4-dihydro-2H-benzo[b][1,4]oxazin-8-yl)urea ([3H]MPOU), that embodies improved absolute affinity for human TRPV1 and improved synthetic accessibility.


Subject(s)
Benzoxazines/pharmacology , TRPV Cation Channels/drug effects , Urea/analogs & derivatives , Animals , Benzoxazines/chemical synthesis , Binding Sites/drug effects , Humans , Protein Binding , Rats , Structure-Activity Relationship , Substrate Specificity , Urea/chemical synthesis , Urea/pharmacology
8.
Eur J Med Chem ; 64: 589-602, 2013 Jun.
Article in English | MEDLINE | ID: mdl-23685943

ABSTRACT

The structure activity relationships of 2-oxy pyridine derivatives in the C-region of N-(6-trifluoromethyl-pyridin-3-ylmethyl) 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamides as hTRPV1 antagonists were investigated. The analysis indicated that the lipophilicity of the 2-oxy substituents was critical for potent antagonism and 4 or 5 carbons appeared to be optimal for activity. Multiple compounds proved to have comparable activity to 1, which had been reported as the most potent antagonist for capsaicin activity among the previous series of compounds. Further analysis of compounds 22 (2-isobutyloxy) and 53 (2-benzyloxy) in the formalin test in mice demonstrated strong analgesic activity with full efficacy. Docking analysis of 53S using our hTRPV1 homology model indicated that the A- and B-region 2-(3-fluoro-4-methylsulfonylaminophenyl)propanamide made important hydrophobic and hydrogen bonding interactions with Tyr511 and that the C-region 6-trifluoromethyl and 2-benzyloxy groups of pyridine occupied the two hydrophobic binding pockets, respectively.


Subject(s)
Benzeneacetamides/pharmacology , Pyridines/pharmacology , Sulfonamides/pharmacology , TRPV Cation Channels/antagonists & inhibitors , Benzeneacetamides/chemical synthesis , Benzeneacetamides/chemistry , Dose-Response Relationship, Drug , Humans , Molecular Structure , Pyridines/chemical synthesis , Pyridines/chemistry , Structure-Activity Relationship , Sulfonamides/chemical synthesis , Sulfonamides/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL